Table 2.

Hormonal response to lanreotide (last value available) analysed by baseline demographic and disease characteristics

	Mean GH ≤ 2.5 ng/ml			Normalized IGF-1			Mean GH ≤ 2.5 ng/ml and normalized IGF-1
	%	n/N	95% CI	%	n/N	95% CI	%	n/N	95% CI
Sex
Female	54.4	31/57	52.1, 79.2	59.6	34/57	45.8, 72.4	45.6	26/57	32.4, 59.3
Male	48.0	24/50	33.7, 62.6	56.0	28/50	41.3, 70.0	36.0	18/50	22.9, 50.8
Age (years)
<40	28.6	4/14	8.4, 58.1	64.3	9/14	35.1, 87.2	28.6	4/14	8.4, 58.1
40–64	55.2	37/67	42.6, 67.4	59.7	40/67	47.0, 71.5	44.8	30/67	32.6, 57.4
65–74	52.6	10/19	28.9, 75.6	47.4	9/19	24.4, 71.1	36.8	7/19	16.3, 61.6
≥75	57.1	4/7	18.4, 90.1	57.1	4/7	18.4, 90.1	42.9	3/7	9.9, 81.6
Baseline mean GH (ng/ml)
<10	66.7	34/51	52.1, 79.2	66.7	34/51	52.1, 79.2	49.0	25/51	34.8, 63.4
≥10	37.5	21/56	24.9, 51.5	50.0	28/56	36.3, 63.7	33.9	19/56	21.8, 47.8
Somatostatin analogue prior treatment
Naive	33.3	5/15	11.8, 61.6	40.0	6/15	16.3, 67.7	20.0	3/15	4.3, 48.1
Not treated within 3 months	38.5	15/39	23.4, 55.4	48.7	19/39	32.4, 65.2	33.3	13/39	19.1, 50.2
Previously treated	68.6	35/51	54.1, 80.9	70.6	36/51	56.2, 82.5	54.9	28/51	40.3, 68.9
Not known	0.0	0/2	0.0, 84.2	50.0	1/2	1.3, 98.7	0.0	0/2	0.0, 84.2
Prior radiotherapy
Yes	41.7	5/12	15.2, 72.3	66.7	8/12	34.9, 901	33.3	4/12	9.9, 65.1
No	52.6	50/95	42.1, 63.0	56.8	54/95	46.3, 67.0	42.1	40/95	32.0, 52.7
Prior pituitary surgery
Yes	59.3	35/59	45.7, 71.9	66.1	39/59	52.6, 77.9	50.8	30/59	37.5, 64.1
No	41.7	20/48	27.6, 56.8	47.9	23/48	33.3, 62.8	29.2	14/48	17.0, 44.1

Combined data Lan-Autogel All